Recently funded awards

This page features a selection of awards we have supported at recent committee meetings.

Select a funding committee below to see what they have funded recently:

Research Bursaries

Dr Sameena Khan, University of Leicester

Investigating a curcumin-binding protein as a potential druggable target in colorectal cancer stem-like cells

Dr Louise Price, University of Birmingham

PRH/pPRH ratio as a marker of response to cisplatin sensitivity

Dr Kiruthikah Thillai, King’s College London

Does the activity of the PAK-PI3K signalling nexus promote pancreatic cancer tissue invasion?

Clinician Scientist Fellowships

Dr Marco Gerlinger, Institute of Cancer Research

Genetic profiling and targeting of heterogeneous and evolving colorectal and renal cancers

Dr Yoryos Lyratzopoulos, University College London

Developing a stratified approach to earlier diagnosis of cancer

Dr Francis Mussai, University of Birmingham

Understanding and targeting the immunosuppressive microenvironment in neuroblastoma

Dr Nischalan Pillay, University College London

Using genomics to identify new therapeutic avenues for patients with unclassifiable sarcomas

Dr Samra Turajlic, CRUK London Research Institute

Mapping clonal evolution in renal cell carcinoma

Late phase clinical trial grants

Kate Cwynarski, University of Southampton

IELSG 42: International phase II trial assessing tolerability and efficacy of sequential MTX/Ara-C-based regimen and R-ICE, followed by high dose chemotherapy supported by PBSCT, in patients with systemic B-cell lymphoma with central nervous system involvement at diagnosis or relapse

Shirley D'Sa, University College London

IDRIS: Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma

Emma Hall, Institute of Cancer Research

CORE:  A randomised trial of conventional care versus radioablation (stereotactic body radiotherapy)for extracranial metastases

Matthew Hatton, NHS Greater Glasgow and Clyde

ADSCaN - A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non Small Cell Lung Cancer

Danish Mazhar, Cambridge University Hospitals NHS Trust

P3BEP Trial Phase 3 Accelerated BEP Trial:  A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Tim Mould and Henry Kitchener, University College London

STATEC:  A randomised trial of non-selective versus selective adjuvant therapy in high risk endometrial cancer

Thomas Powles and Robert Jones, University of Glasgow

ATLANTIS - Maintaining response in urothelial cancer: A personalised precision medicine trial

Tom Treasure, University College London

Pulmonary metastasectomy in colorectal cancer (PulMiCC): A Randomised trial of Pulmonary Metastasectomy in Colorectal Cancer

Jonathan Wadsley, Sheffield Teaching Hospitals NHS Foundation Trust

SEL-I-METRY: Investigating the potential clinical benefit of selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy


Sample collection grants

Richard Adams and Nicholas West, University College London

ARISTOTLE sample collection

Ruth Langley and David Cameron, University College London

Prospective sample collection for translational research within the Add-Aspirin trial

Somnath Mukherjee, University of Oxford

T-SCALOP2: Prospective sample collection in the SCALOP2 trial


Feasibility study grants

Simon Bach and David Sebag-Montefiore, University of Birmingham

STAR-TREC: Single port TransAnal surgery and Radiotherapy versus Total mesorectal excision for early REctal Cancer

James Larkin and Paul Nathan, Royal Marsden NHS Foundation Trust

PERM: A Randomised Phase II Study Assessing Enhancement of Response to MK3475 by High Dose Palliative Radiotherapy in Patients with Advanced Melanoma


Clinical trial fellowships

Julia Brown and Jenny Seligmann, University of Leeds

Robert Jones and Ben Fulton, University of Glasgow

Pamela Kearns and Kathryn Herring, University of Birmingham

Mark Middleton and Victoria Woodcock, University of Oxford

Drug Discovery Project Awards

Adrian Whitehouse, University of Leeds

Next generation antivirals for the treatment of Kaposi’s sarcoma

John Brognard, University of Manchester

LZK: A Novel Target for Therapeutic Intervention in Head and Neck Squamous Cell Carcinoma

Matthew Fuchter and Robert Brown, Imperial College London

Development of dual EZH2/EHMT2 inhibitors for the treatment of solid tumours

Aymen Al-Shamkhani, University of Southampton

Monoclonal antibody targeting of TNF receptor superfamily member 25 to promote anti-tumour immunity.


CRUK and Bayer Healthcare co-funded Drug Discovery Project Awards

Anthony Chalmers, University of Glasgow

Identifying and validation of novel targets for overcoming radiation resistance of glioblastoma stem cels under normoxia and hypoxia

Margaret Ashcroft, University of Cambridge

Target identification and mechanism of action studies prior to lead optimization of novel hypoxia/hypoxia inducible factor signalling inhibitors

John Maher, King's College London

Development of gamma delta (gd) T-cell immunotherapy for triple negative breast cancer (TNBC)

Paola Scaffidi, Barbara Nicke and Martin Lange, The Francis Crick Institute

Identification of Epigenetic Mechanisms regulating Cancer Stem Cell Formation and Function

Project Awards

Katriina Whitaker, University of Surrey

Understanding socioeconomic differences in help-seeking for breast cancer symptoms in the UK

Julie Walabyeki and Una Macleod, University of Hull

Age linked factors and help seeking behaviour: a qualitative study exploring the effect of older people's fatalistic attitudes towards ill health and dying

Sara Macdonald and Shona Hilton, University of Glasgow

An exploration of the media representation of cancer and its impact on older adults' understanding of cancer risk and help-seeking behaviour

Cristina Renzi, University College London

Missed opportunities for earlier cancer diagnosis along the diagnostic pathway and effect on colorectal cancer diagnosis following emergency presentation: importance of healthcare and patient-related factors

David Weller and Domenica Coxon, University of Edinburgh

Understanding how 'lung cancer symptoms' and 'service' factors drive the decision to seek help from a GP in the Scottish public: a discrete choice experiment

Project Grants

Professor Jane Wardle, University College London

Developing and testing targeted invitation materials to increase uptake of lung cancer screening in communities at high risk of lung cancer 

Dr Kate Brain, University of Cardiff 

Development and pilot evaluation of the Tenovus health check: a targeted cancer awareness intervention for people from deprived communities

Dr Georgios Lyratzopolous, University of Cambridge

What is driving general practice variation in ‘two-week wait’ referrals and use of endoscopy and imaging investigations, and does it matter for cancer outcomes?

Professor Andrew Renehan, University of Leicester

Development of a risk prediction tool for early cancer detection in patients with type 2 diabetes

Dr Peter Murchie, University of Aberdeen

Does place of residence, distance and travelling times from health services within Northeast Scotland influence the diagnostic pathway and outcomes from eight common cancers: analysis of a linked dataset

NAC Preclinical Grants

Elizabeth Tucker and Louis Chesler, The Institute of Cancer Research

An investigation into the treatment of neuroblastoma with mutations of Anaplastic Lymphoma Kinase (ALK), using LDK378 and LEE011 combination therapy targeting ALK and Cyclin-dependent Kinase (CDK) 4/6, in a preclinical transgenic neuroblastoma model

Caroline Dive, Cancer Research UK Manchester Institute

Assessment of the anti-tumour efficacy and pharmacodynamic effects of combining the Wee1 inhibitor AZD1775 with small cell lung cancer standard of care chemotherapy cisplatin/etoposide or topotecan in unique small cell lung cancer circulating tumour cell derived xenograft models

Caroline Dive, Cancer Research UK Manchester Institute

Assessment of the anti-tumour efficacy and pharmacodynamic effects of combining the Wee1 inhibitor AZD1775 with the Hsp90 inhibitor AT13387 in unique lung cancer circulating tumour cell derived xenograft models


NAC Trial Grants

Simon Crabb, University of Southampton

SPIRE: A Phase Ib/IIa clinical trial combining DNA Methyltransferase inhibitor SGI110 with cisplatin and gemcitabine chemotherapy in patients with advanced solid tumours including bladder cancer

Career Development Fellowship

Dr Anna Chambers, University of Bristol

The function of the Irc5 subfamily of chromatin remodelling enzymes in DNA repair

Dr Luis Baena Lopez, University of Oxford

Subcellular regulation and non-apoptotic function of caspases during proliferation and differentiation of stem cells

Dr Jo Waller, University College London

Using behavioural science to maximise the impact of cervical cancer control policies

Dr Carmela De Santo, University of Birmingham

Investigating the immunosuppressive microenvironment created by Acute Myeloid Leukaemia using invariant Natural Killer T cells as a novel therapeutic approach

Dr Jurre Kamphorst, University of Glasgow

The effect of tumour microenvironment on the metabolism of pancreatic cancer cells

Dr Binzhi Qian, University of Edinburgh

The role(s) of macrophages in breast cancer bone metastasis

Dr Elli Papaemmanuil, Wellcome Trust Sanger Institute

Interpret: Clinical and biological implications of acquired somatic mutations in myeloid neoplasms

Career Establishment Award

Dr Walid Khaled, University of Cambridge

Cellular and Molecular Characterisation of Breast Cancer Heterogeneity

Dr Dirk Sieger, University of Edinburgh

In vivo studies of microglia-glioma interactions

Senior Cancer Research Fellowship

Dr Steven Pollard, University of Edinburgh

The role of SOX and FOX genes in orchestrating transcriptional and epigenetic programs in glioblastoma

Dr Ingo Ringshausen, University of Cambridge

Characterization of signalling pathways underlying bi-directional communications with the microenvironment in B lymphoproliferative diseases

Research Travel Awards

Dr Kirsty Greenow, University of Cambridge

Isolation, culture and analysis of mouse ovarian surface epithelial cells and ovarian stem cells

Dr Karen Evans-Reeves, University of Bath

Knowledge Exchange: Exploring the relationships between tobacco control organisations and their key stakeholders

Dr Gerry Crossan, University of Cambridge

Mechanisms of alcohol induced tumorigenesis

Programme Grants

Bernard Rachet, London School of Hygiene and Tropical Medicine

Cancer survival

Richard Martin and Caroline Relton, University of Bristol

Reducing the burden of cancer: causal risk factors, mechanistic targets and predictive biomarkers

Timothy Key, University of Oxford

The epidemiology and aetiology of high risk prostate cancer

Project Grants

Julia Scarisbrick, University Hospital Birmingham NHS Foundation Trust

A Multicentre Prospective Study in Mycosis Fungoides and Sezary Syndrome To Develop an International Prognostic Index

Catherine Meads, Brunel University

Sexual orientation and smoking - an evaluation using the Smoking Toolkit Study

Lesley Anderson and Liam Murray, Queen's University Belfast

Infectious agents in progression from Barrett's Oesophagus to Oesophageal Adenocarcinoma, a nested case control study within the Northern Ireland Barrett’s Register

Dr Chris Cardwell, Queen’s University Belfast

A novel, integrated, bioinformatics and pharmacoepidemiology approach to identifying and testing medications with potential breast cancer carcinogenicity, or anti-cancer properties

Professor Marijn de Bruin, University of Aberdeen

Making results of smoking cessation trials more useful to policy and practice: Identifying the effective behavioural components of smoking cessation support provided to intervention and control groups by applying innovative methods for evidence syntheses

Professor Paul Lambert, University of Leicester

Development and application of statistical methods to maximize the increased opportunities made available in the UK with more detailed population-based cancer data

Professor Eve Roman, University of York

Quantification of antecedent events and outcomes in patients with haematological malignancies: analysis of a unique population-based matched patient cohort

Dr Christian von Wagner, University College London

Identifying demographic and psychosocial predictors of flexible sigmoidoscopy screening intentions and uptake

Dr James Wason, MRC Cambridge

Improving the power of phase II oncology trials through the use of continuous tumour measurements

Population Research Postdoctoral Fellowship

Alice Forster, University College London

Why are girls from Black and Asian minority ethnic backgrounds less likely to receive the human papillomavirus (HPV) vaccine? Developing and testing a complex psychological intervention to increase informed uptake

Samuel Smith, Queen Mary, University of London

Poison or prevention: do cognitive representations of breast cancer chemoprevention affect adherence

Charlene McShane, Queen's University Belfast

Population-based register of monoclonal gammopathy of undetermined significance (MGUS): establishing risk prediction models and investigating patient outcomes

Programme Awards

Eric Miska, University of Cambridge

Non-coding RNA and cancer: new mechanisms and therapeutic opportunities

Albena Dinkova-Kostova, University of Dundee

The role of the Keap1/Nrf2 pathway in tumour metabolic adaptation

Anne Donaldson, University of Aberdeen

How does Rif1 ensure chromosome stability and can its removal prevent tumour cell survival?

David Bishop and Julia Newton-Bishop, University of Leeds

Genetic epidemiology of melanoma susceptibility and survival

Louis Chesler, Institute of Cancer Research

Improving outcomes for childhood neuroblastoma - development of therapeutics targeting MYCN, ALK and tumour-initiating pathways

David Kelsell, Queen Mary, University of London

iRHOM/ADAM17 in oesophageal squamous cell cancer

Uwe Oelfke, Institute of Cancer Research

Advances in Physics for Precision Radiotherapy

Duncan Baird, Cardiff University

Examining telomere dysfunction, fusion and the escape from crisis in human cells

Freddie Hamdy, University of Oxford

Investigation of novel molecular imaging techniques for precision surgery and genomic characterisation of high-risk prostate cancer

Joanna Morris, University of Birmingham

Ubiquitin processing in cancer development and treatment

Deborah Goberdhan and Eric O’Neill, University of Oxford

Role of rapamycin-resistant mTORC1 as a major regulator of exosome secretion, content and function in adaptation to the microenvironment

Professor Christopher Schofield, University of Oxford

Biochemical and cellular characterisation of histone demethylases

Professor Yvonne Jones, University of Oxford

The structural biology of recognition and signalling at the cell surface

Professor Rosalind Eeles, Institute of Cancer Research

Translational studies in prostate cancer genetics: an oncogenetics programme

Professor Markus Müschen, University of Cambridge

Pre-B cell receptor checkpoint control in acute lymphoblastic leukaemia

Professor Tim Illidge, University of Manchester

Developing effective combinations of radiotherapy and immunotherapy in cancer

Professor Buzz Baum, University College London

Environmental control of cancer cell division: role of the mitotic cortex

Dr Reuben Tooze, University of Leeds

Plasma cell (PC) quiescence and the origins of myeloma

Professor Alison Lloyd, University College London

Identification of novel therapeutic targets in biogenic and regenerative pathways

Professor Leonard Seymour, University of Oxford

Potentiating oncolytic virotherapy by cancer-selective expression of biologics

Professor Vincenzo Cerundolo, University of Oxford

Development of vaccination strategies to enhance tumour specific immune responses

Professor Henning Walczak, University College London

Understanding and harnessing TRAIL’s pro-tumourigenic and pro-apoptotic in-vivo functions for improved cancer therapy

Biomarker Project Awards

Professor Diana Eccles, University of Southampton

Prospective study of Outcomes in Sporadic versus Hereditary breast cancer

Professor Susan Burchill, University of Leeds

Qualification of target mRNAs as prognostic and predictive biomarkers in children with high-risk neuroblastoma

Dr Gerald Saldanha, University of Leicester

A blood test for melanoma – detection and analysis of tumour-derived circulating free DNA by deep sequencing (The MELSEQ Study)

Professor Catharine West, University of Manchester

Prospective qualification of a hypoxia metagene biomarker in a randomised placebo controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab (NIMRAD-METAGENE)

Project Grants

Olivia Maynard, University of Bristol

Using cognitive neuroscience to improve the effectiveness of tobacco health warnings

Amanda Amos, University of Edinburgh

Young adults' understandings and experiences of e-cigarettes

Adam Crosier, Word of Mouth Research

Cut Films: evaluating a filmmaking and social media peer education intervention to prevent the uptake of smoking among young people

Jamie Brown, University College London

The ‘real-world’ associations between e-cigarette use and smoking cessation: A prospective cohort study

Ann McNeill, King's College London

Secondary analysis of e-cigarette survey data

Funding committees

Successful applicant case studies

Find out how our current grantees successfully applied for funding.

Read more

Our Research Prizes

Do you know somebody whose exceptional research merits reward and recognition? Nominate the rising stars and inspiring leaders of cancer research for our Research Prizes by 31 March.

Find out more

Share this page